Regulated information

Rapport semestriel 2007 « narratif » (french)

Suite à la publication du 26 juillet dernier, Vétoquinol a réalisé au 1er semestre 2007 un
chiffre d’affaires de 111,1 M€ contre 98,4 M€ au cours de la même période de l’exercice
précédent, soit une progression de 12,9 %.
A cours de change et périmètre constants, la progression est de 10,1 %.

Reports very good first half, confirming that 2007 performance is set to surpass targets

Presentation of Vétoquinol’s results for the first half of 2007

2007 Half year results

3rd quarter revenues confirm promise of
strong growth prospects for 2007

For the nine months ended September 30, 2007, Vétoquinol’s total revenues reached €166.0 M, an increase of 11.3% compared with the
corresponding period in 2006.

Vétoquinol to market and distribute Vetprofen in the United States

Vétoquinol announces opening of its first decentralized R&D center in Canada

Revenue grows by 10.3% in 2007, to €233.4 M

KIBOW BIOTECH INC. et Vétoquinol S.A. étendent leur accord de commercialisation et de licence vétérinaire pour des applications mondiales (french)

VÉTOQUINOL S.A. and JUROX PTY LTD extend their collaboration on ALFAXAN® in Europe

Earnings for 2007 attest to strength of business growth model

The Vétoquinol board of directors, meeting on February 22, 2008, reviewed the group’s business in 2007 and approved the related financial statements. In 2007, Vétoquinol once again achieved significant improvement in its key performance
indicators, ahead of its medium-term targets. According to the most recent statistics published by Vetnosis, this substantial rise in revenue has lifted Vétoquinol to third place
worldwide.